[ET Net News Agency, 23 October 2025]  CSPC PHARMA (01093) fell 2.8% to HK$8.22.
  It hits an intra-day low of HK$8.2, hitting an 1-month low, and an intra-day high of  
HK$8.44. The total shares traded was 26.6 million, with a value of HK$220.47m. The active 
buy/sell ratio is 47:53, with net selling turnover of HK$14.63m. MERRILL LYNCH FE accounts
for greatest net responsive buying turnover of HK$18.73m, with volume weighted average  
price of HK$8.287. JEFFERIES HK accounts for greatest net responsive selling turnover of  
HK$6.4m, with volume weighted average price of HK$8.321. The stock has fallen a combined  
8.9% over the past 3 consecutive trading days.
  The Hang Seng Index now fell 75 points, or 0.3% to 25,705; the Hang Seng China  
Enterprises Index now fell 32 points, or 0.4% to 9,191. 
  
          Basic Information 
          ================= 
  
  --------------------------------- 
  Nominal   8.220 % Chg     -2.84%
  High      8.440 Low        8.200
  Shares Tr 26.6m Turnover 220.47m
  10-D SMA  8.881 %H.V      49.386
  20-D SMA  9.110 VWAP       8.288
  50-D SMA  9.857 RSI14     34.587
  --------------------------------- 
Status: Hitting an 1-month low, active buy/sell ratio is 47:53, with net selling turnover 
of HK$14.63m, falling a combined 8.9% over the past 3 consecutive trading days
  
Performance of stocks in the same sector or of relevance
========================================================
  
  Stock (Code)            Price (HK$) Change (%)
  ----------------------------------------------- 
  CSPC PHARMA (01093)            8.22      -2.84
  SINO BIOPHARM (01177)          7.00      -2.78
  HENGRUI PHARMA (01276)        77.05      -1.28
  INNOVENT BIO (01801)          86.05      +1.00
  WUXI BIO (02269)              35.36      -1.28
  WUXI APPTEC (02359)          105.20      -0.75
  HANSOH PHARMA (03692)         34.52      -1.32
  UNITED LAB (03933)            13.04      -0.53
  BEONE MEDICINES (06160)      184.80      -0.38
  AKESO (09926)                114.80      -1.46
  ----------------------------------------------- 
  (ed)



 
 